Kiniksa Pharmaceuticals, Ltd. Financials

Market Capitalization $1.43 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	164.31
Forward PE	35.95
Price to Sales TTM	$3.72
Price to Book MRQ	$3.26
Enterprise to Revenue	3.16
Enterprise to EBITDA	-49.76

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	-2.36%
Operating Margin	-8.61%
Return on Assets TTM	-3.16%
Return on Equity TTM	-2.15%

Income Statement

Revenue TTM	$384,097,984
Revenue per Share TTM	$5.42
Quarterly Revenue Growth	67.40%
Gross Profit TTM	$234,439,008
EBITDA	$-24,401,000
Net Income to Common TTM	$-9,068,000
Diluted EPS TTM	$-0.12
Quarterly Earnings Growth YoY	67.37%

Balance Sheet

Total Cash MRQ	$223,780,000
Total Cash per Share MRQ	$3.10
Total Debt MRQ	$
Total Debt to Equity MRQ	2.42
Current Ratio MRQ	3.24
Book Value per Share MRQ	$6.06

Cash Flow

Operating Cash Flow TTM	$11,244,000
Levered Free Cash Flow TTM	$25,738,500

KNSA Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	41,566,800
Float Shares	15,291,569
Avg 10 Volume	560,000
Avg 30 Volume	None
Shares Short	3,388,499
Short Ratio	9.47
Short % of Shares	10.49%
% Held by Insiders	4.10%
% Held by Institutions	98.05%

Stock Price Summary

Beta	0.35
Fifty Two Week Low	$16.56
Fifty Two Week High	$28.15
Fifty Two Week Change	8.19%
Day 50 MA	$20.64
Day 200 MA	$21.89

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date